IP Verse

Glp-1 Receptor Agonists In Dementia - EP4054620

The patent EP4054620 was granted to Novo Nordisk on May 29, 2024. The application was originally filed on Nov 5, 2020 under application number EP20803489A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4054620

NOVO NORDISK
Application Number
EP20803489A
Filing Date
Nov 5, 2020
Status
Granted And Under Opposition
Apr 27, 2024
Grant Date
May 29, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKFeb 27, 2025ADMISSIBLE
SANDOZFeb 7, 2025ADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0046182
DESCRIPTIONWO0192206
DESCRIPTIONWO2006097537
DESCRIPTIONWO2007121318
DESCRIPTIONWO2008028859
DESCRIPTIONWO2011080103
DESCRIPTIONWO2012140117
DESCRIPTIONWO2015155151
DESCRIPTIONWO9630036
DESCRIPTIONWO9808871
INTERNATIONAL-SEARCH-REPORTUS2017112897
INTERNATIONAL-SEARCH-REPORTWO2017112889
OPPOSITIONUS2017112897
OPPOSITIONUS2019142905
OPPOSITIONWO2012080471
OPPOSITIONWO2017112889
OPPOSITIONWO2021089678

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- ANDRE F BATISTA ET AL, "The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease : Liraglutide protects memory, insulin receptors, and synapses", THE JOURNAL OF PATHOLOGY, (20180402), vol. 245, no. 1, doi:10.1002/path.5056, ISSN 0022-3417, pages 85 - 100, XP055682460 [I] 11-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- WATSON KATHLEEN T ET AL, "Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, (20180809), vol. 356, doi:10.1016/J.BBR.2018.08.006, ISSN 0166-4328, pages 271 - 278, XP085492161 [I] 11-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- ZHANG LIPING ET AL, "Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model", NEUROPEPTIDES, CHURCHILL LIVINGSTONE, GB, (20180711), vol. 71, doi:10.1016/J.NPEP.2018.07.003, ISSN 0143-4179, pages 70 - 80, XP085482793 [I] 1-3,6-10 * Discussion * [A] 4,5
INTERNATIONAL-SEARCH-REPORT- STEPHEN N. GOMPERTS,, "Lewy Body Dementias : Dementia With Lewy Bodies and Parkinson Disease Dementia", CONTINUUM - LIFELONG LEARNING IN NEUROLOGY: THE OFFICIAL CME JOURNAL OF THE AMERICAN ACADEMY OF NEUROLOGY, US, (20160401), vol. 22, no. 2, Dementia, doi:10.1212/CON.0000000000000309, ISSN 1080-2371, pages 435 - 463, XP055767450 [A] 1-10 * the whole document *
INTERNATIONAL-SEARCH-REPORT- YAN YANG ET AL, "Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes1", JOURNAL OF ALZHEIMER'S DISEASE, NL, (20130924), vol. 37, no. 3, doi:10.3233/JAD-130491, ISSN 1387-2877, pages 637 - 648, XP055682486 [X] 11 * Abstract, discussion * [I] 12-15
INTERNATIONAL-SEARCH-REPORT- LIPING ZHANG ET AL, "Semaglutide is Neuroprotective and Reduces [alpha]-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease", JOURNAL OF PARKINSON'S DISEASE, NL, (20190205), vol. 9, no. 1, doi:10.3233/JPD-181503, ISSN 1877-7171, pages 157 - 171, XP055767444 [I] 1-3,6-10 * Results * [A] 4,5
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - RYBELSUS (semaglutide) tablets, for oral use", FDA, (20190901), vol. 13, no. 1, doi:10.1038/s41598-023-30240-8, pages 1 - 24, XP093261795-
OPPOSITION- Anonymous, "Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes ", novo nordisk, (20180209), XP093261768-
OPPOSITION- D26 - Epub of TM12 October 14, 2020-
OPPOSITION- Nn, "Assessment report Ozempic International non-proprietary name: semaglutide", URL: https://www.ema.europa.eu/en/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf, (20200715), XP055715141-
OPPOSITION- Yang, "Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes", IOS Press, vol. 37, page 3, IOS Press, URL: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad130491, (20200402), XP055682483-
OPPOSITION- Wang William, Wang Quangqiu, Qi Xin, Gurney Mark, Perry George, Volkow Nora D., Davis Pamela B., Kaelber David C., Xu Rong, "Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US", Alzheimer's & Dementia, ELSEVIER, NEW YORK, NY, US, US , (20241201), vol. 20, no. 12, doi:10.1002/alz.14313, ISSN 1552-5260, pages 8661 - 8672, XP093261783
OPPOSITION- Andre F Batista, Leticia Forny-Germano, Julia R Clarke, Natalia M Lyra E Silva, Jordano Brito-Moreira, Susan E Boehnke, Andrew Winterborn, Brian C Coe, Ann Lablans, Juliana F Vital, Suelen A Marques, Ana Mb Martinez, Matthias Gralle, Christian Holscher, William L Klein, Jean-Christophe Houzel, Sergio T Ferreira, Douglas P Munoz, Fernanda G De Felice, "The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease : Liraglutide protects memory, insulin receptors, and synapses", The Journal of Pathology, Longman, Hoboken, USA, Hoboken, USA, (20180501), vol. 245, no. 1, doi:10.1002/path.5056, ISSN 0022-3417, pages 85 - 100, XP055682460
OPPOSITION- V. Calsolaro, P. Edison, "Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, AUCKLAND, NZ , (20151201), vol. 29, no. 12, doi:10.1007/s40263-015-0301-8, ISSN 1172-7047, pages 1023 - 1039, XP009560980
OPPOSITION- Andre F. Batista, Victor Bodart-Santos, Fernanda G. De Felice & Sergio T. Ferreira , "Neuroprotective Actions of Glucagon‑Like Peptide‑1 (GLP‑1) Analogues in Alzheimer’s and Parkinson’s Diseases", CNS DRUGS 12 2018, Springer International Publishing, (20181203), vol. 33, no. 3, doi:10.1007/s40263-018-0593-6, ISSN 1179-1934, pages 209 - 223, XP009560979
OPPOSITION- V. Boccardi et al., "Diabetes drugs in the fight against Alzheimer's disease", Ageing Research Reviews , (2019), vol. 54, doi:10.1016/j.arr.2019.100936, XP085763058
OPPOSITION- Watson Kathleen T.; Wroolie Tonita E.; Tong Gabby; Foland-Ross Lara C.; Frangou Sophia; Singh Manpreet; McIntyre Roger S.; Roat-Shumway Siena; Myoraku Alison; Reiss Allan L.; Rasgon Natalie L., "Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease", BEHAVIOURAL BRAIN RESEARCH., ELSEVIER, AMSTERDAM., NL, NL , (20180809), vol. 356, doi:10.1016/j.bbr.2018.08.006, ISSN 0166-4328, pages 271 - 278, XP085492161
OPPOSITION- Yildirim Simsir Ilgin, Soyaltin Utku Erdem, Cetinkalp Sevki, "Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease", Diabetes & Metabolic Syndrome: Clinical Research & Reviews, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20180501), vol. 12, no. 3, doi:10.1016/j.dsx.2018.03.002, ISSN 1871-4021, pages 469 - 475, XP093261778
OPPOSITION- Chang Yan-fang; Zhang Di; Hu Wei-min; Liu Dong-xing; Li Lin, "Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis", JOURNAL OF CLINICAL NEUROSCIENCE, CHURCHILL LIVINGSTONE, GB, GB , (20201014), vol. 81, doi:10.1016/j.jocn.2020.09.054, ISSN 0967-5868, pages 234 - 239, XP086357668
OPPOSITION- L. Zhang et al., "Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model", Neuropeptides, (20180711), vol. 71, doi:10.1016/j.npep.2018.07.003, XP085482793
OPPOSITION- Cheignon C., Tomas M., Bonnefont-Rousselot D., Faller P., Hureau C., Collin F., "Oxidative stress and the amyloid beta peptide in Alzheimer’s disease", Redox Biology, Elsevier, NL, NL , (20180401), vol. 14, doi:10.1016/j.redox.2017.10.014, ISSN 2213-2317, pages 450 - 464, XP093261775
OPPOSITION- D.A. Butterfield et al., "Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease", Nature Reviews Neuroscience , (2019), vol. 20, doi:10.1038/s41583-019-0132-6, XP037237828
OPPOSITION- Schühlen H., "Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?", European Heart Journal, Oxford University Press, GB, GB , (20140801), vol. 35, no. 31, doi:10.1093/eurheartj/ehu202, ISSN 0195-668X, pages 2055 - 2057, XP093261770
OPPOSITION- Femminella Grazia Daniela, Frangou Eleni, Love Sharon B., Busza Gail, Holmes Clive, Ritchie Craig, Lawrence Robert, Mcfarlane Brady, Tadros George, Ridha Basil H., Bannister Carol, Walker Zuzana, Archer Hilary, Coulthard Elizabeth, Underwood Ben R., Prasanna Aparna, Koranteng Paul, Karim Salman, Junaid Kehinde, Mcguinness Bernadette, Nilforooshan Ramin, Macharouthu Ajay, Donaldson Andrew, Thacker Simon, Russell Gregor, Malik Naghma, Mate Vandana, Knight Lucy, Kshemendran Sajeev, Harrison John, Brooks David J., Passmore Anthony Peter, Ballard Clive, Edison Paul, "Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)", TRIALS, BIOMED CENTRAL, LONDON, GB, GB , (20191201), vol. 20, no. 1, doi:10.1186/s13063-019-3259-x, ISSN 1745-6215, XP093112388
OPPOSITION- Stephen N. Gomperts,, "Lewy Body Dementias : Dementia With Lewy Bodies and Parkinson Disease Dementia", CONTINUUM - Lifelong Learning in Neurology: The Official CME Journal of the American Academy of Neurology, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, US , (20160401), vol. 22, no. 2, Dementia, doi:10.1212/CON.0000000000000309, ISSN 1080-2371, pages 435 - 463, XP055767450
OPPOSITION- L. Zhang et al., "Semaglutide is neuroprotective and reduces [alpha]-synuclein levels in the chronic MPTP mouse model of Parkinson's disease", Journal of Parkinson's Disease, (20190205), vol. 9, doi:10.3233/JPD-181503, page 1, XP055767444
OPPOSITION- Lotte Bjerre Knudsen, Lau Jesper, "The Discovery and Development of Liraglutide and Semaglutide", Frontiers in Endocrinology, vol. 10, doi:10.3389/fendo.2019.00155, pages 1 - 32, XP055658646
OPPOSITION- Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B. Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht, Niels Møller, Birgitte Brock, Jørgen Rungby, "In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial", Frontiers in Aging Neuroscience, vol. 8, doi:10.3389/fnagi.2016.00108, XP055682463

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents